BAJAJHCARE Bajaj Healthcare Q2 FY27 results (Jul–Sep 2026) and concall
Bajaj Healthcare had a strong Q2 FY27: revenue rose 18.9% YoY to ₹175.9 crores and PAT rose 26.9% to ₹14.1 crores. Growth came from an ~82% rebound in formulations, helped by the Cenobamate launch, and 28.5% growth in export API, which offset a sharp sequential fall in domestic API. Management reaffirmed FY27 guidance of 10-15% growth at an 18-20% margin and set a target of ₹900-1,000 crores revenue by FY29. Planned growth drivers include a peptide plant (March 2027), an oncology API plant (Q2 FY28), a Nashik formulation plant (Q1 FY28) and the NCLT-approved Genrx acquisition. Working capital
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY27: revenue up 18.9%, net profit up 27.3% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 123 | 154 | 149 | 148 | 161 +31% | 153 −1% | 166 +11% | 176 +19% |
| EBITDA | 22 | 12 | 25 | 27 | 31 +41% | 23 +92% | 29 +16% | 31 +15% |
| Net profit | 12 | 11 | 12 | 11 | 16 +33% | -23 −309% | 14 +17% | 14 +27% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
